Clinical trialNCT06980077RecruitingPhase 2Interventional

Ivonescimab for the Treatment of Thymic Cancer

SponsorJonsson Comprehensive Cancer CenterEnrollment25Thymus Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jonathan W Goldman
UCLA / Jonsson Comprehensive Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California at Davis (ucd)
Davis, California, United States
Surbhi Singhai, MD
Not, yet, recruiting
University of California at Irvine (uci)
Irvine, California, United States
Zhaohui Ann Arter, MD
Not, yet, recruiting
Ucla / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Jonathan W. Goldman
Recruiting
University of California at San Francisco (ucsf)
San Francisco, California, United States
Matthew Grubens, MD
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Jennifer Marks, MD
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ivonescimab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Jul 2025
Primary completion: 17 Jun 2027
Completion: 17 Jun 2028
Last update posted: 7 Jul 2026
Registered enrollment: 25
Registry id: NCT06980077

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.